---
layout: default
title: Turoctocog Alfa
parent: Model Prediction Only (L5)
nav_order: 810
evidence_level: L5
indication_count: 10
---

# Turoctocog Alfa
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Turoctocog Alfa: From Factor VIII Deficiency (Hemophilia A) to Primary Release Disorder of Platelets

## One-Sentence Summary

> Turoctocog alfa is a recombinant Factor VIII replacement therapy, originally used for Factor VIII deficiency (Hemophilia A).
> The TxGNN model predicts it may be effective for **Primary Release Disorder of Platelets**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications**, and mechanistic review flags a poor match.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Factor VIII deficiency (Hemophilia A) *(inferred from drug class; no Taiwan/Canada regulatory label text available)* |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, turoctocog alfa is a recombinant coagulation Factor VIII product used to replace deficient or missing FVIII in patients with Hemophilia A, restoring the intrinsic coagulation cascade.

The top-ranked predicted indication, primary release disorder of platelets, is a platelet **function** disorder (defective granule release), not a coagulation **factor** deficiency. The evidence pack's own mechanistic analysis concludes that this is a mechanism mismatch: replacing Factor VIII does not correct defective platelet granule release, since the two disorders act on entirely different steps of hemostasis (secondary coagulation vs. primary platelet-mediated hemostasis).

This suggests the very high TxGNN score likely reflects a statistical/network-topology association (e.g., shared "bleeding disorder" node neighborhoods in the knowledge graph) rather than a true pharmacological rationale. Among the ten predicted indications in this evidence pack, only rank 5 ("acquired coagulation factor deficiency") shows a mechanistically plausible link to FVIII replacement; several others (e.g., thrombotic thrombocytopenic purpura) are flagged as potentially contraindicated rather than beneficial. This pattern indicates the prediction set requires mechanistic triage before any further evaluation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Turoctocog alfa is currently **not marketed** in Canada (market status: Not marketed / Not Marketed) and has **0 registered DINs**. No product license records are available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA label warnings/contraindications data is flagged as a Blocking data gap (DG001) — this must be resolved before any safety pre-assessment (S1) can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top predicted indication has an evidence level of L5 (no clinical trials, no literature, model prediction only), and the mechanistic review explicitly identifies a mismatch between Factor VIII replacement and platelet release/function disorders. Combined with a Blocking data gap on TFDA safety labeling and a High-severity gap on MOA, this candidate does not meet the threshold to advance past S0.

**To proceed, the following is needed:**
- Resolve DG001: obtain TFDA (or equivalent) label warnings/contraindications before any safety pre-assessment
- Resolve DG002: confirm detailed MOA via DrugBank API to properly assess mechanistic fit
- Independent mechanistic re-screening of the 10 candidates — prioritize rank 5 ("acquired coagulation factor deficiency"), which is the only candidate with a plausible FVIII-replacement rationale
- Explicitly flag rank 9 (thrombotic thrombocytopenic purpura) as a potential safety concern rather than a repurposing candidate, given the theoretical thrombosis risk
- Real-world or preclinical evidence generation, since no clinical trials or literature currently exist for any of the top 10 candidates
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

